WCM Investment Management LLC Has $4.30 Million Stake in Haleon PLC Sponsored ADR $HLN

WCM Investment Management LLC boosted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 16.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 486,633 shares of the company’s stock after acquiring an additional 67,192 shares during the quarter. WCM Investment Management LLC’s holdings in Haleon were worth $4,302,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HLN. Brighton Jones LLC bought a new position in shares of Haleon in the 4th quarter valued at $187,000. AQR Capital Management LLC boosted its stake in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after purchasing an additional 17,720 shares in the last quarter. Focus Partners Wealth grew its holdings in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after purchasing an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after buying an additional 1,203 shares during the period. Finally, Hilltop National Bank bought a new position in Haleon in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Down 0.6%

Shares of NYSE:HLN opened at $10.50 on Wednesday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $9.96 and its 200 day moving average is $9.64. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The stock has a market cap of $46.74 billion, a price-to-earnings ratio of 26.91 and a beta of 0.19.

Analysts Set New Price Targets

HLN has been the subject of several analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Hsbc Global Res upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.